Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Girentuximab Zr 89 - Heidelberg-Pharma/Telix-Pharmaceuticals

Drug Profile

Girentuximab Zr 89 - Heidelberg-Pharma/Telix-Pharmaceuticals

Alternative Names: 177Lu-DOTA-girentuximab; 89Zirconium-labelled Girentuximab; 89Zr-DFO-TFP-girentuximab (GTX); 89Zr-girentuximab; 89Zr-TLX250; 89Zr-DFO-girentuximab; 89Zr-TX250; TLX250 CDx; Zircaix; Zirconium-89 girentuximab; Zr-89-girentuximab

Latest Information Update: 06 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator WILEX AG
  • Developer China Grand Pharmaceutical and Healthcare; Heidelberg Pharma AG; Institut de Cancerologie de l'Ouest; Radbound University Nijmegen; Telix Pharmaceuticals; University of Melbourne
  • Class Diagnostic agents; Imaging agents; Monoclonal antibody diagnostics; Radioisotopes; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Renal cell carcinoma
  • Phase II Solid tumours; Triple negative breast cancer
  • Phase I Bladder cancer; Urogenital cancer
  • Research Colorectal cancer

Most Recent Events

  • 31 Jan 2024 Telix Pharmaceuticals completes the phase-II OPALESCENCE trial in Triple-negative-breast cancer (Diagnosis) in France (IV), prior to January 2024 (NCT04758780)
  • 19 Dec 2023 Preregistration for Renal cell carcinoma (Diagnosis) in USA (IV)
  • 06 Dec 2023 Positive efficacy and adverse events data from a phase II OPALESCENCE trial in Triple negative breast cancer presented at the San Antonio Breast Cancer Symposium® (SABCS-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top